Valeant reduces debt to $25.4B — 3 insights

Valeant Pharmaceuticals will redeem $150 million in aggregate principal senior unsecured notes due in 2020, reducing its debt to $25.4 billion, May 14.

Advertisement

Here’s what you should know.

1. The notes were originally issued in 2012. Valeant will repay the debt using cash on hand.

2. Valeant Chairman and CEO Joseph Papa said, “Due to strong operational cash flow, we are able to further reduce our debt. As part of our ongoing transformation, we will continue to pay down our debt and invest in our core businesses for growth.”

3. Mr. Papa has made several commitments to pay down Valeant’s debt, and he continues to chip away at the remaining balance.

More articles on supply chain:
Copper Ridge Surgery Center awarded for patient care initiative — 5 highlights
Acrometis and PriceMDs bring bundled pricing to workers’ comp space — 5 notes
Humana expands orthopedic bundled payment model to 7 more states

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Supply chain

Advertisement

Comments are closed.